Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease

A method for inhibiting unwanted non-malignant lymphoproliferation associated with an inflammatory disease,

• wherein the inflammatory disease is diarrhea;
• autoimmune disease;
• proliferative glomerulonephritis;
• lupus erythematosus;
• scleroderma;
• temporal arteritis;
• thromboangiitis obliterans;
• mucocutaneous lymph node syndrome;
• asthma;
• host versus graft;
• or inflammatory bowel disease;
• and wherein
• said method comprising the step of contacting a cell the proliferation of which contributes to inflammation in situ with an effective amount of a compound having the formula:
• or a pharmaceutically acceptable salt or hydrate thereof, wherein:
• n is 0, 1, 2, 3 or 4;
• X is absent, (C1-C3) alkyl, (C1-C3) alkenyl, or (C1-C3) alkynyl;
• Y is C, N, P, Si or Ge;
• R1 is absent, -halo, —R, —OR, —SR, —NR2, —ONR2, —NO2, —CN, —C(O)R, —C(S)R, —C(O)OR, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NR2, —C(S)NR2, —C(O)NR(OR), —C(S)NR(OR), —C(O)NR(SR), C(S)NR(SR), —CH(CN)2, —CH[C(O)R]2, —CH[C(S)R]2, —CH[C(O)OR]2, —CH[C(S)OR]2, —CH[C(O)SR]2, —CH[C(S)SR]2 or aryl;
• Ar1 is aryl, substituted aryl, heteroaryl other than imidazole, nitroimidazole and triazole, heteroarylium other than imidazolium, nitroimidazolium and triazolium, (C5-C8) cycloalkyl or (C5-C8) heterocycloalkyl;
• Ar2 is aryl or substituted aryl;
• Ar3 is aryl, substituted aryl, biaryl or heteroaryl other than imidazole, nitroimidazole and triazole;
• each R is independently selected from the group consisting of —H, (C1-C6) alkyl, substituted (C1-C6) alkyl, (C1-C6) alkenyl, substituted (C1-C6) alkenyl (C1-C6) alkynyl, substituted (C1-C6) alkynyl, and (C1-C6) alkoxy;
• the aryl substituents are each independently selected from the group consisting of -halo, trihalomethyl, —R, —R′, —OR′, —SR′, NR′2, —NO2, —CN, —C(O)R′, —C(S)R′, —C(O)OR′, —C(S)OR′, —C(O)SR′ and —C(S)SR′;
• the alkyl, alkenyl and alkynyl substituents are each independently selected from the group consisting of -halo, —R′, —OR′, —SR′, NR′2, —NO2, —CN, —C(O)R′, —C(S)R′, —C(O)OR′, —C(S)OR′, —C(O)SR′, —C(S)SR′, aryl, γ-butyrolactonyl, pyrrolidinyl and succinic anhydridyl;
• and
• each R′ is independently selected from the group consisting of —H, (C1-C6) alkyl, (C1-C6) alkenyl and (C1-C6) alkynyl;
• wherein said administration is selected from the group consisting of oral, parenteral, intravenous, subcutaneous, transdermal and transmucosal for a living human.